On 1 December, Roche held a symposium at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Diego (USA), sharing interim results of the Brainshuttle Phase Ib/IIa proof-of-concept study with trontinemab in people with early Alzheimer’s disease (AD). Presented results focused on cohorts in which participants received trontinemab 1.8mg/kg or 3.6mg/kg every four weeks for 28 weeks and showed rapid and robust amyloid lowering with trontinemab treatment, especially at the higher 3.6 mg/kg dose. The overall safety profile was consistent, showing a favourable safety and tolerability profile. Additionally, Roche has recently launched two identical global Phase III studies, TRONTIER 1 and TRONTIER 2, to assess the clinical efficacy and safety of trontinemab in people with early symptomatic AD. The trials are planned to enrol 1,600 participants across 18 countries (800 per study). The company also highlighted the TRAVELLER master pre-screening study, designed to reduce participant burden and broaden access to clinical trials in AD.
